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Abstract
Analysis of Chlamydia pneumoniae and AD-like Pathology in the Brains of BALB/c
Mice Following Direct Intracranial Infection with Chlamydia pneumoniae
Jessica Rachel Barton
MS in Biomedical Sciences, August 2011
Department of Pathology, Microbiology, Immunology and Forensic Medicine
Philadelphia College of Osteopathic Medicine, Philadelphia, PA

C. Scott Little, Ph.D. Thesis Advisor
Alzheimer’s disease (AD) is an age-related progressive neurodegenerative
disorder and the most common form of dementia. The pathology in the central nervous
system (CNS) impairs memory and cognition, hindering the capabilities and the quality
of life of the individual. This project continues studying the role of infection and
Alzheimer’s disease and contributes to the overall understanding of the possible causes of
this disease. In this study, BALB/c mice were infected, via direct intracranial injection,
with a respiratory isolate (AR-39) of Chlamydia pneumoniae. Their brains were
analyzed at 7 and 14 days post-infection, using immunohistochemistry, for the presence
of C. pneumoniae, amyloid deposits and activated glial cells. The goal of this project was
to measure the location and degree of C. pneumoniae burden, amyloid deposition and
glial cell activation in the CNS following direct intracranial injection and to compare this
data with results obtained from previous studies in this laboratory. We hypothesized that
C. pneumoniae antigen and activated inflammatory cells will be observed in the infected
ii

mouse brains following direct intracranial injection and Aβ deposition will be observed in
areas where inflammation occurs. C. pneumoniae, amyloid deposits and activated glial
cells were detected in the brains following direct intracranial infection with C.
pneumoniae. At 7 days post-infection the average number of C. pneumoniae-specific
immunoreactive sites was 68 ± 51.06 for the infected mice and, at 14 days post-infection,
the average was 60 ± 43.79 for the infected mice. Within 0.84 mm of Bregma, the
location of the injection, 166 of 203 total C. pneumoniae-specific immunoreactive sites
(82%) and 26 of 27 (96%) total amyloid deposits were detected at 7 days post-infection.
At 14 days post-infection, 126 of 179 total C. pneumoniae-specific immunoreactive sites
(70%) and 13 of 32 (41%) total amyloid deposits were detected (within 0.84 mm of
Bregma). From 7 to 14 days post-infection the C. pneumoniae and amyloid deposits
located near the injection site spread distally from this location to other regions of the
brain. These data confirm that C. pneumoniae is capable of establishing an infection in
the CNS. Although deposits were observed, the lack of a substantial amount of amyloid
deposits suggested that the generation of deposits may require longer than 14 days
following C. pneumoniae infection. As early as 7 days post-infection, inflammation is
observed in response to the presence of C. pneumoniae and/or soluble amyloid in the
CNS and the contribution of both infection with C. pneumoniae and the presence of
soluble amyloid elicit the inflammatory response that presumably precedes and
contributes to amyloid deposition.
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1

Introduction

I.

Alzheimer’s Disease

Alzheimer’s disease (AD), the most common form of dementia in elderly
individuals, is an age-related, progressive neurodegenerative disease that produces
memory loss and severe cognitive impairment [1-3]. This form of dementia accounts for
50-60% of all dementia cases, currently affecting more than 15 million people worldwide
[2]. According to the 2010 annual report from the Alzheimer’s Association, 5.3 million
people in the United States (U.S.) are suffering from this disease and the U.S. is currently
spending approximately 172 billion dollars per year on associated costs [4]. This number
of affected individuals and the associated costs places a clear strain on the healthcare
system and society as a whole. Alzheimer’s disease greatly impacts the quality of life of
the individual, their family members, friends and caregivers. Throughout the past
century significant progress in the study of AD has been made, which contributes to our
understanding of AD and our ability to slow the progression of the disease in patients.
However, it is important to build upon past research and gather new information so that
the cause, and ultimately the cure, for AD can be determined.
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II.

Forms of Alzheimer’s Disease and Neuropathology

In 1911, Alois Alzheimer described Alzheimer’s disease as a mental disorder in
elderly individuals characterized by two lesions in the brain. His work led to further
investigations of individuals with this disorder and research that has contributed to our
observation and understanding of the two forms of AD: familial, early-onset (FAD) and
sporadic, late-onset AD (LOAD). Familial AD, which typically occurs prior to age 65, is
an autosomal dominant disorder [2]. In contrast the onset of LOAD is not primarily due
to a genetic disorder and instead it increases with age, generally occurring after age 65.
Late-onset AD is much more prevalent than FAD, accounting for approximately 95% of
all AD cases [3, 5].
Neuropathology shared by the two forms of AD presents as two defining
hallmarks of the disease: neurofibrillary tangles (NFTs) and neuritic (senile) plaques
(NSPs). Tangles are paired filaments of the abnormally hyperphosphorylated form of the
tau protein, which accumulate in the perikaryal cytoplasm of neuronal cells. Plaques are
extracellular accumulations of amyloid β (Aβ) peptide [3, 6-8]. The presence of Aβ
plaques is thought to lead to neuronal dysfunction and death. The deposition of these
plaques may promote hyperphosphorylation of tau and elicits a local inflammatory
response, both of which will also contribute to additional injury and death of neurons [3].
Although we do not know what the function of amyloid β peptide is after normal
processing, we do know that the peptide is produced throughout life and is derived from

3

the amyloid precursor protein (APP). The amyloid precursor protein is a transmembrane
protein that has cleavage sites for the following enzymes: α-secretase, β-secretase and γsecretase [3]. If APP is cleaved by α-secretase and γ-secretase Aβ formation is
prevented, but if APP is cleaved by β-secretase and γ-secretase then the result is Aβ
generation (Figure 1).
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[3]

Figure 1. Amyloid Precursor Protein (APP) Proteolytic Cleavage

A) APP is synthesized in many cells and expressed as a transmembrane protein at the cell
surface. When APP is present at the surface of the cell there are three enzymes - α-, βand γ- secretase – that function to cleave this protein at corresponding cleavage sites on
APP. B) Cleavage by α-secretase releases a soluble portion of APP into the extracellular
environment and γ-secretase cleaves APP so that a portion remains internalized in the
cell. C) When β- and γ-secretases act on APP, Aβ will be produced and released into the
extracellular environment where it will readily form fibrils of Aβ peptide [3].
Generation of Aβ produces monomers of Aβ1-40 and Aβ1-42 [9]. Amyloid β1-40 is
the major form of cellular Aβ in the brain and is fairly soluble compared to Aβ1-42, the
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longer form of this peptide, which is fairly insoluble [10]. Amyloid β peptides, Aβ1-40
and Aβ1-42, are found in both normal and AD brains; however the proportions and the
extent of burden differ. Plaques are composed of silver-staining neuritic processes that
surround an extracellular deposit of Aβ, also known as the central amyloid core of the
plaque [3]. Amyloid β1-42 aggregates more readily to form the central amyloid core in
NSPs than Aβ1-40 and is considered to be toxic to neurons [9, 10]. As all individuals age,
Aβ will accumulate in the brain as the rate of Aβ formation increases with age. This rate
increase is presumably due to a change in enzymatic activity, which is supported by
previous observations in FAD cases [3].
Genetic risks have been linked to both forms of the disease. Individuals suffering
from FAD have genetic defects that affect these pathways and cause Aβ to accumulate
earlier and more rapidly. Familial AD involves mutations in APP and the transmembrane
proteins presenilin-1 (PS-1) and presenilin-2 (PS-2) genes, all of which will lead to
altered processing and thus accumulation of Aβ peptides in the brain [2, 5, 7].

These

mutations are not responsible for LOAD, however, an association between apolipoprotein
E (ApoE) ε4 allele and onset of LOAD has been recognized [2, 5, 11, 12]. The presence
of this allele does not guarantee development of the disease as seen with the direct
correlations between genetic mutations and onset of familial Alzheimer’s disease. Two
additional ApoE alleles, ε2 and ε3, generate the ApoE2 and ApoE3 isoforms, but it is the
ε4 allele that accounts for the highest genetic risk associated with the development and
rate of progression of LOAD [2].
Individuals who have the ε4 allele are at greater risk for developing LOAD and
their cognitive functioning declines more rapidly than those lacking this allele, however,
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people who do not have this allele may still get AD [13]. Due to the ability of this
isoform to bind to Aβ, ApoE4 may contribute to plaque formation and reduction of Aβ
clearance [14]. Those who have the genotypes ε2/ε4, ε3/ε4 and ε4/ε4 are at increased
risk for the development of AD [15]. The ε3 allele is the most common of the three
alleles, accounting for approximately 75% of all alleles and ε2 is the least common
accounting for only about 10% [12, 14].

Individuals with genotypes ε2/ε2 or ε2/ε3 have

a decreased risk of developing the disease and the age of onset of AD is typically later
compared to individuals that possess one or more ε4 alleles [14, 15]. As previously
mentioned, the presence of the ε4 allele does not guarantee AD development. The
presence of this allele increases one’s risk of developing AD which is diagnosed based on
cognitive function and memory impairment and confirmed at autopsy.
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III.

Diagnosis and Clinical Manifestations

Alzheimer’s disease is diagnosed using cognitive evaluations in living patients
and is only confirmed at autopsy. A number of tests for evaluation and diagnosis, such as
the mini mental status exam (MMSE), test various areas of cognitive function at the time
the first symptoms are recognized, as well as over time to track the course of cognitive
decline in the patient [16, 17].
Advancements in in-vivo technology, including magnetic resonance imaging
(MRI) and positron emission tomography (PET), aid in the detection of changes of
pathology in the central nervous system (CNS) and allow for comparison of healthy
brains with those of individuals diagnosed with the disease. These imaging systems
identify atrophy of the hippocampus and entorhinal cortex in human AD brains of living
patients, which is supported by post-mortem examination upon death [2]. Although
diagnosis of AD is only confirmed at autopsy, neuronal degeneration and the production
of the two hallmark pathologies begins much earlier in specific regions of the brain
leading to observable changes in the mental and physical status of the patient; and thus
the clinical diagnosis of the disease in a living person [2, 16, 17].
The clinical manifestations of AD, such as loss of memory and cognitive decline,
result from the dysfunction and death of neuronal cells, which will disrupt the biological
processes in the affected regions of the brain, eventually spreading to the entire brain by
the end-stage of the disease [16, 18].

Pathologic changes begin in the transentorhinal
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cortex and the olfactory bulb is also thought to be one of the first areas affected [13],
subsequently extending into the amygdala and hippocampal formation. Pathology can be
observed in the frontal, temporal and occipital association areas as well. Ultimately
pathology extends into the cerebral cortex, including the isocortex and neocortex [18,
19].
In 1991, Braak and Braak defined AD as a series of four stages that illustrates the
progression of pathology and changes in various brain regions, a system widely utilized
amongst AD researchers today. According to their research, the transentorhinal cortex,
located between the entorhinal cortex and temporal isocortex, contains the first nerve
cells affected in most cases of Alzheimer’s disease. Following these observations they
found pathology in and further involvement of the entorhinal region and the
hippocampus. At this point they found that the isocortex still remains mostly unaffected.
Pathology may also be observed in frontal, temporal and occipital association areas at this
stage of the disease. Extensive pathology in the transentorhinal, entorhinal and
hippocampal regions is expressed and their final stage describes pathology extending into
the isocortex in addition to the previously mentioned affected regions [18].
Clinicians find that the clinical symptoms in the patient are consistent with the
regions of the brain affected by neuronal degeneration and pathology over the course of
this progressive neurodegenerative disease. For example, current studies have found
pathology in the olfactory bulbs very early in the disease, which is consistent with some
of the first symptoms of AD including lost sense of taste and smell [13]. AD patients
initially present with extreme impairment of recent memory and decreased cognition,
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which is consistent with pathology in the limbic system, which includes the entorhinal
region, hippocampus and amygdala [5, 19, 20]. The hippocampus is an area of the brain
critical in the formation of new memory, the entorhinal cortex is the primary source of
afferents to the hippocampus, and the amygdala is involved in the emotion-related
aspects of memory and learning [19]. Many researchers have contributed to our
understanding of the pathology observed in and the clinical diagnosis of AD, however,
the underlying causes of this disease are not as well-defined.

IV.

Possible Causes of Alzheimer’s Disease

The progress that has been made allowing us to understand, diagnose and treat
Alzheimer’s disease is remarkable. However, we are still working to discover the cause
of LOAD so that we may eventually be able to determine a cure for the disease. A
number of hypotheses have been proposed to explain the onset of Alzheimer’s disease.
The hypothesis that has the most data to support it is the amyloid cascade hypothesis
[21].
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a. Amyloid Cascade Hypothesis

The proposal of the amyloid cascade hypothesis plays a major role in AD research
today as the focus shifts for some laboratories from treating AD to determining the cause
of this disease. It was proposed by J. Hardy and G. Higgins, and also supported by D.
Selko, in the early 1990’s and states that there is an imbalance between production and
clearance of Aβ ultimately leading to Aβ deposition, promoting neuronal degeneration
and dysfunction, which is characteristic of both familial and sporadic forms of AD [2, 21,
22]. This hypothesis has been widely accepted since the finding that mutations in the
genes for APP and presenilins, which are the substrate and enzyme for Aβ generation,
have been implicated in FAD [2, 13]. As previously stated, the genetic mutations
identified in patients with FAD are not responsible for the development of LOAD, but the
neuropathology observed in both forms of the disease is identical.
There are many cases of elderly individuals who have extensive Aβ deposition
identified at autopsy, even though they never presented with the clinical symptoms of AD
while living [22, 23]. The amyloid cascade hypothesis correlates well with FAD where
we observe onset of this form of AD as pathology increases. However, this hypothesis
does not always fit for late-onset Alzheimer’s disease since the amount of pathology is
not always associated with the time of onset of the disease. Therefore, although Aβ may
be involved in the pathophysiology of LOAD, it is only part of a larger picture. The
initiating events leading to the onset of LOAD are not as well understood as those
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contributing to FAD onset. Further research is necessary to determine the causative
factors for the development of the late-onset form of the disease.

b. Infection

Neuropathology in both FAD and LOAD are similar, however, the reason this
pathology is observed in the brains of individuals with LOAD remains unclear. Multiple
possible causes of LOAD, a multifactorial disease, are recognized, including the role of
infectious organisms. Researchers working to determine the cause of LOAD have
observed an association between pathology in the AD brain and the onset of
neuroinflammatory processes, which locally up-regulate inflammatory mediators when
damaged neuronal cells, plaques and tangles are present [5-7, 24]. These studies support
the fact that the brain, similar to other tissues in the body, is susceptible to infection.
Furthermore, infectious agents can take several routes of entry to the CNS and may cause
damage by directly injuring cells in the nervous system or through an indirect
pathway/process that produces adverse effects due to an inflammatory or immunemediated response [3, 13, 23].
In the study of LOAD, several viral and bacterial pathogens have been studied for
their ability to establish an infection in the CNS that may contribute to neuropathology
seen in Alzheimer’s disease [13, 25]. Infection with Herpes simplex virus type 1 (HSV1) has been identified as a risk factor for the development of AD in certain individuals
[25]. These are the individuals with at least one of the ε4 alleles for the ApoE gene. This
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is the allele that accounts for the highest genetic risk for the development and rate of
progression of late-onset Alzheimer’s disease [2].

c. Chlamydia pneumoniae

Our laboratory focuses on infection with C. pneumoniae, a bacterial pathogen
gaining significant attention for its role in numerous chronic diseases, in particular AD
[7, 23, 26, 27]. Chlamydia pneumoniae is an obligate intracellular bacterial pathogen that
infects mucosal surfaces of the respiratory tract [28-30]. C. pneumoniae is generally
transmitted person-to-person through aerosolized droplets to the respiratory tract and can
disseminate systemically, typically infecting and “hitching a ride” inside monocytic cells,
although it has been shown to be capable of infecting an array of human cell types [13,
23, 31, 32]. Like other chlamydial species, C. pneumoniae is characterized by a biphasic
developmental cycle. The first phase is defined by the activity of an infectious
metabolically inactive elementary body (EB) attaching to target cells of the host and
uptake into a vacuole, and the second phase by a dividing, intracellular, metabolically
active reticulate body (RB). The developmental cycle starts with the conversion of EB to
the growth form, RB, which then divides and usually reverts back to the EB form and is
released from the host cell to continue propagating the infection [5, 13, 29].
Chlamydia pneumoniae infection has been associated with the onset and
progression of several chronic diseases [13, 33]. For example, studies have observed a
correlation between infection with this organism and coronary artery disease as
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C. pneumoniae has been identified in plaques associated with atherosclerosis [26, 34].
Adult populations that have been tested show seroprevalence over 40% worldwide [32,
33]. This organism is wide-spread in society often producing infections that are
asymptomatic and in response to the host immune reaction the organism adapts and
enters a persistent/non-replicative state, which may promote a chronic infection. It is
thought that the pathogenesis of this persistent state may be associated with chronic
disease development [13, 29].
This lab has developed a mouse model of AD-like pathology in which amyloid
deposits have been experimentally induced following infection with a human AD-isolate
of the organism C. pneumoniae [5, 7]. This model is useful for exploring the early events
that take place in LOAD as well as the role of infection, particularly with the organism C.
pneumoniae, in the induction of neuroinflammation and AD pathogenesis.
In recent experiments [7], BALB/c mice were infected, intranasally, with a
respiratory isolate of C. pneumoniae (AR-39) and their brains were isolated following
perfusion at 1, 2, 3, or 4 months post-infection (unpublished observations). Brains of
experimentally infected or mock-infected age and sex matched mice were analyzed via
immunohistochemistry using antibodies specific for amyloid or C. pneumoniae antigens.
The greatest amount of C. pneumoniae was detected at 1 month post infection, and then
decreased at 2, 3 and 4 months post infection. The amount of Aβ deposition peaked at 2
months post-infection, which suggests that C. pneumoniae is capable of establishing a
CNS infection and promoting amyloid deposition, which may serve as a stimulus for
inflammation in the brain. Therefore, the presence of amyloid plaques in the brains of
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the infected mice was likely a consequence of an inflammatory response to infection
(unpublished observations).

d. Inflammation

Chronic inflammation is a hallmark of AD, however, whether the inflammatory
response results from the over expression of Aβ or other stimuli is yet to be determined
[26]. The accumulation of Aβ in the CNS leads to amyloid β deposits, a key feature of
the pathogenesis of Alzheimer’s disease. Amyloid β is known to lead to the dysfunction
and death of neuronal cells in its presence [3, 9]. The initiating factors of LOAD are still
unknown, but research in this laboratory suggests that infection may be the initial source
for inflammation and thus the development of AD-like pathology [7, 13].
The resident immune and phagocytic cells of the CNS, microglia, are the initial
sensors of pathogens or changes in the brain environment [35]. Microglia are stimulated
by the presence of soluble amyloid, the type present prior to forming a deposit, or
insoluble amyloid, deposits or plaques [9, 17]. Microglia and astrocytes are capable of
binding both soluble and insoluble amyloid, via specific receptors that are recognized by
the Aβ peptide, and Aβ aggregates have also been shown to activate microglia and
astrocytes [24, 35]. Following binding to Aβ, microglia become “activated,” which is
defined as cells that have an altered shape and size of their cell bodies, lengths of their
processes, as well as functional changes compared to “resting” microglia. Once in the
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active state, the microglia will phagocytize any material they recognize as disrupting the
homeostasis of the CNS, including amyloid. Microglia will also respond by secreting
inflammatory mediators and proteolytic enzymes or neurotrophic factors that influence
astrocytes, another type of glial cell, and neurons inducing secondary inflammatory
responses [9, 35]. The glial response will resolve once infection is cleared or damaged
tissues have been repaired, thus preventing disease in the short term. However, when the
presence of the inflammatory stimulus persists or the normal resolution mechanisms fail,
sustained or chronic inflammation results and this glial response may contribute to the
progression of disease [35].
The role of glia in AD is still not well understood, but astrogliosis and changes in
microglia morphology that are observed in AD brains provides evidence of an
inflammatory response in AD [35]. Studies using transgenic mouse models for AD have
shown that the amount of microglia in the CNS increases with increased levels of
amyloid plaques, as early as two months of age [36]. Another group [37], working with a
β-site APP cleavage enzyme (BACE1) [3] transgenic mouse model of AD, has observed
microglial activation earlier than two months of age and even before observing the
presence of amyloid deposits in the CNS . This illustrates the possibility that microglia
may respond to altered APP processing that can lead to eventual accumulation of amyloid
in the CNS [37]. The ability of microglia to detect and respond to injury or the presence
of pathogens in the brain is crucial for maintaining homeostasis and consequently normal
processing and functioning in the CNS. However, continuous activation of these immune
cells may lead to chronic inflammation and thus the progression of disease [9, 38].
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Both the high prevalence of infection with C. pneumoniae in the population and
the presence of inflammation in the CNS, a common observation in both Chlamydiainduced diseases and the AD brain, led this laboratory to its decision to investigate a
possible relationship between C. pneumoniae and Alzheimer’s disease in the late 1990’s.
Several studies in this laboratory have also confirmed the presence of C. pneumoniae in
areas of the AD brain presenting with neuropathology [7, 13, 26]. Balin et al compared
postmortem brain samples from patients with and without AD and found that in brain
areas with typical AD related neuropathology 89% of the AD patients were positive for
C. pneumoniae and 95% of the non-AD control brains were negative for this organism
[26]. Another group studying the response of microglia to infection with C. pneumoniae,
[38], observed an increase in the number of activated microglial cells in the brains of C.
pneumoniae PCR-positive mice compared to infected PCR-negative and mock infected
mice. Based on the data obtained and the correlations observed between C. pneumoniae
and AD in previous experiments, this lab continues investigating the role of infection
with this organism and late-onset Alzheimer’s disease. This laboratory is working to
confirm that inflammation induced following infection with C. pneumoniae promotes the
generation and deposition of amyloid β.
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V.

Study Directive and Hypothesis

Previous experiments have illustrated the ability of C. pneumoniae to get into the
CNS and produce AD-like pathology (Aβ 1-42) [7, 11, 26]. Although Aβ 1-42 deposits
were detected via immunohistochemistry, it did not co-localize with C. pneumoniae in
these studies, suggesting the inflammatory response to the presence of C. pneumoniae
may play a role in Aβ 1-42 formation.
This laboratory has not previously studied the effects of direct intracranial
infection with C. pneumoniae in model animals for Alzheimer’s disease. This project
aims to expand on the knowledge and data gained from our previous studies, where mice
were infected intranasally. We will investigate the presence of C. pneumoniae antigen,
activated glial cells and Aβ deposition in fixed and embedded mouse brain tissue that was
previously infected, via direct intracranial injection, with C. pneumoniae. The goal of the
proposed research is to measure the location and degree of amyloid deposition, C.
pneumoniae antigen and glial cell activation in the CNS following direct intracranial
injection.
To contribute to our understanding of the role of infection with C. pneumoniae in
AD this project aims to:
1) determine the amount of pathogen needed to initiate/produce pathology
2) determine the mobility of the pathogen in the CNS once present
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3) determine the presence and location of activated glial cells and compare this to
regions where C. pneumoniae and/or Aβ is observed
4) compare these results with previous data in order to further elucidate how this
may contribute to progressive pathology in other regions of the brain

We hypothesize that C. pneumoniae antigen and activated inflammatory cells will be
observed in the infected mouse brains following direct intracranial injection and Aβ
deposition will be observed in areas where inflammation occurs.
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Materials and Methods

I.

Chlamydia pneumoniae

BALB/c mice were infected with 1 x 105 infectious units, of a human respiratory
isolate of C. pneumoniae, AR-39, obtained from the American type Culture Collection
(ATCC), and propagated in HEp-2 cells, isolated for these experiments. Infectious units
were administered via direct intracranial injection. Hank’s balanced salt solution (HBSS)
vehicle alone was given intracranially for age and sex matched uninfected control mice.
(Table 1)

II.

Infection of Mice and Brain Removal

Female BALB/c mice were infected, intracranially, with C. pneumoniae. The
injection site is located at approximately Bregma -2.12mm on the anatomical right side of
the mouse brain (Figure 2). At 7 or 14 days post-infection the mice were sacrificed and
perfused with 4% paraformaldehyde. Their brains were immersion fixed in 4%
paraformaldehyde for more than 48 hours. The fixed tissue was embedded in paraffin
and then sectioned coronally at 7-10 microns thickness.
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III.

Mouse Brain

A total of 50 brain coronal sections were immunolabeled per mouse: 4 sets (1 per
primary antibody) and 1 set (secondary antibody only) for both the rostral and caudal
portions of the brains – 5 sections were labeled for each set. The immunolabeled sections
were 7-10 microns thick and spaced equally at 35-50 micron intervals. Samples represent
regions spanning from rostral (bregma + 2.22mm) to caudal (bregma – 5.88mm). (Figure
3)

IV.

Antibodies

Primary antibodies specific for C. pneumoniae: mouse monoclonal RDIPROAC1p used at a working concentration of 1:10 (Research Diagnostics Incorporated,
Flanders, NJ), mouse monoclonal M6600 also used at a working concentration of 1:10
(DakoCytomation, Carpinteria CA), and mouse monoclonal 10C-27 used at a working
concentration of 1:100 (Fitzgerald, Concord MA). Primary antibodies specific for
amyloid beta 1-42 antigens: rabbit polyclonal Aβ 1-42 used at a working concentration of
1:300 (Oncogene Research Products) and mouse monoclonal Aβ 1-42 (6E10) used at a
working concentration of 1:500 (Covance). The primary antibody specific for glial
fibrillary acidic protein (GFAP) was mouse, anti-human monoclonal GFAP used at a
working concentration of 1:25 (AbD Serotec, Raleigh, NC). Alkaline phosphatase
conjugated secondary antibodies were utilized to visualize the respective antigens of
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interest. All antibodies were diluted to working concentration in phosphate buffer saline
– blocking buffer (Table 2).

V.

Immunohistochemistry

Coronal sections (see Materials and Methods subsection Mouse Brain) were rehydrated by melting the wax for 30 seconds, followed by xylene – 3 minutes (3x)
(Thermo Fisher Scientific, Pittsburgh PA), rehydrated in a series of graded alcohol
solutions – 100% ethanol for 3 minutes (2x), 90% ethanol for 3 minutes (1x) and 70%
ethanol for 3 minutes (1x) (Electron Microscopy Sciences, Fort Washington PA),
followed by DI H2O for 3 minutes. Next, slides were placed in Citra antigen retrieval
buffer (BioGenex, San Roman CA) and steamed in a 2010 Retreaver (Pick Cell
Laboratories, Amsterdam Netherlands) for 20 minutes at high pressure (120oC). Slides
remained in antigen retrieval buffer overnight at room temperature.
Slides were rinsed with phosphate buffer saline (PBS) pH 7.4 (Sigma-Aldrich, St.
Louis MO) 3 x 5 minutes. Endogenous peroxidase activity was quenched utilizing a 3%
solution of H2O2/PBS (stock 30%, Thermo Fisher Scientific, Pittsburgh PA) for five
minutes at room temperature. Sections were rinsed 1 x 5 minutes in PBS and blocked
three times in 2% heat inactivated fetal bovine serum (FBS)/PBS (Mediatech, Herndon
VA). Primary antibodies Aβ1-42, Aβ6E10, mixed “cocktail” of 10C-27, AC1P, M6600,
or GFAP (Table 2) were applied to tissue sections and placed in a humidified chamber at
37oC for 90 minutes. The sections were rinsed 3 x 5 minutes each and then blocked 3 x
15 minutes each in 2% FBS/PBS, then incubated with appropriate secondary antibodies
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in a humidified chamber for 60 minutes at 37oC. Following incubation, sections were
rinsed with distilled water 3 x 5 minutes and developed using alkaline phosphatase new
magenta for fifteen minutes (BioFX, Owings Mills MD). Next, sections were rinsed in
distilled water 3 x 5 minutes followed by one PBS rinse for 5 minutes. Acidified Harris’s
Hematoxylin (Mercury free) was applied to sections for 1 minute (Thermo Fisher
Scientific, Pittsburgh PA). Sections were rinsed thoroughly in distilled water and then
were contrasted in PBS for 5 minutes. The sections were rinsed with distilled water 3 x 5
minutes, air dried, and crystal mounted (BioMeda, Foster City CA) and air-dried
overnight. Once dry, the sections were permounted (Fisher Chemicals, Fair Lawn NJ)
and coverslipped.

VI.

Microscopic Analysis

Microscopic examination of tissue was completed using 10x, 20x, 40x and 60x
objectives. Digital still images were captured using NIS-Elements F 2.20 Imaging
System software on a Nikon Eclipse 50i microscope using a Nikon Digital Sight DS-SM
Camera.

VII.

Mapping Immunolabeling on Mouse Coronal Schematics:

Each coronal section viewed was matched to a representative coronal section
from the Mouse Brain Library (http://www.mbl.org/). These representative sections were
used to illustrate immunolabeling seen in the corresponding brain section.
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Table 1. Study design

Control (no injection)
Control (vehicle)
Infected

7 Days Post-Infection
n=0/5
n=1/1
n=3/5

14 Days Post-Infection
n=1/5
n=0/1
n=3/5

A total of 11 mice were prepared for each time point – 5 control (no injection), 1
control (vehicle) and 5 infected. All of the infected mice were infected via direct
intracranial injection with C. pneumoniae. The control mice were either injected with
vehicle only (HBSS) or not injected. For this project a total of four mice were analyzed
for the day 7 time point – one vehicle only control mouse and three experimental mice –
and a total of four mice were analyzed for the day 14 time point – one no injection
control and three experimental mice.

24

Table 2. Antibodies
Antibody
Name
AC1P
RDIPROAC1p
(10R-C124a)

Supplier

Antigen
Recognized

Conc.
(mg/mL)

Species

Conjugate

Research Diagnostics
Incorporated, Flanders
NJ (Fitzgerald,
Concord MA)

Cpn
lipopolysaccharide

0.05

Mouse,
monoclonal
IgG3

NA

M6600

DakoCytomation,
Carpinteria CA

Cpn major
outer
membrane
protein

1:10*

Mouse,
monoclonal
IgG

NA

10C-27

Fitzgerald, Concord
MA

Cpn

1.05

Aβ 1-42

Oncogene Research
Products

Aβ 1-42

0.391

Aβ 1-42
(6E10)

Covance

Aβ 1-42

1.0

AbD Serotec, Raleigh,
NC

Glial
fibrillary
acidic
protein

1:25*

Zymed Laboratories,
San Francisco CA

NA

2.0

Goat,
anti-mouse

Alk, Phos.

Zymed Laboratories,
San Francisco CA

NA

2.0

Goat,
anti-rabbit

Alk. Phos.

GFAP
AP-Goat
anti-mouse
IgG
AP-Goat
anti-rabbit
IgG

Mouse,
monoclonal
IgG
Rabbit,
polyclonal
IgG
Mouse,
monoclonal
IgG
Mouse,
anti-human,
monoclonal
IgG1

NA

NA

NA

NA

‘Cpn’ = C. pneumoniae. * No concentration was provided, only volumes were given by
manufacturers, along with suggested working dilutions.
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Figure 2. Injection Site.

The boxed area on the image above represents the approximate location of the
injection site in the mouse brain – Bregma -2.12 mm [39].
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Figure 3. Anatomic Locations of Representative Coronal Sections

The numbers and corresponding lines above are 1 mm apart from one another.
The regions boxed in red indicate the location of the injection site. The brains were
sliced coronally starting, at line 2 above, approximately, and then separated into two
halves – rostral (BrA) and caudal (BrB). From this initial slice (at line 2) the two halves
were serially sectioned, every 35-50 microns and at a thickness of 7-10 microns, in both
the rostral and caudal directions – see small arrows at the top of the figure [39].

27

Results

For each time point, 7 and 14 days post-infection, a total of 4 mice – 3 infected
and 1 uninfected – were analyzed for the presence of C. pneumoniae antigen, amyloid
deposits and activated glial cells.

I.

Identification of C. pneumoniae Antigen in the CNS

Following direct intracranial infection, C. pneumoniae antigens were detected, via
immunohistochemistry, in the CNS of the mice. As described earlier (see Materials and
Methods subsection Mouse Brain), a total of 80 coronal brain sections, 10 per mouse,
were immunolabeled for C. pneumoniae and analyzed via microscopy. Both typical
intracellular C. pneumoniae-specific labeling (Figure 4B and 4C) and some atypical
extracellular labeling (Figure 4A) was observed.
The day 7 time point included three mice infected with C. pneumoniae and one
control mouse injected with vehicle only (HBSS). C. pneumoniae antigen was detected
via immunohistochemistry in all mice at this time point (Table 3). Two of the three
infected mice displayed 129 and 70 immunoreactive sites, which was greater than the 27
immunoreactive sites detected in the vehicle injected control, for this time point. A total
of 4 immunoreactive sites were detected in the third infected mouse for this time point.
The average C. pneumoniae antigen burden for the infected mice at this time point was
68 ± 51.06. Within 0.84 mm of Bregma (the location of the injection site) in both the
rostral and caudal directions, 166 of 203 (82%) C. pneumoniae-specific immunoreactive
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sites were detected (Table 5). Chlamydia pneumoniae was observed in regions of interest
in AD, such as thalamus, hippocampus and entorhinal cortex, as well as areas not
significantly affected early on in the disease (Figure 7, left column).
At 14 days post-infection histologic samples from three mice infected with C.
pneumoniae and one no-injection control mouse were analyzed. Similar to what was
observed at the day 7 time point, C. pneumoniae antigen was detected via
immunohistochemistry in all mice at this time point (Table 3). Two of the three infected
mice displayed 111 and 64 immunoreactive sites, greater than the 18 sites observed in the
uninfected, no-injection, control mouse for this time point. The third infected mouse in
this group had 4 immunoreactive sites. The average C. pneumoniae antigen burden for
the infected mice at this time point was 60 ± 43.79. Only 126 of 179 (70%) C.
pneumoniae-specific immunoreactive sites were detected proximal to the injection site,
within 0.84 mm of Bregma (Table 5). Chlamydia pneumoniae was observed in regions
of interest in AD, such as thalamus, hippocampus and entorhinal cortex, as well as areas
not significantly affected early on in the disease (Figure 8, left column).

II.

Identification of Amyloid Deposits in the CNS

Following direct intracranial infection with C. pneumoniae, a small number of
amyloid deposits were observed, via immunohistochemistry, in the CNS of the mice. As
described earlier (see Materials and Methods subsection Mouse Brain), a total of 160
coronal brain sections, 20 per mouse, were immunolabeled for amyloid β and analyzed
via microscopy. Twice as many slides were analyzed for amyloid, compared to C.
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pneumoniae. Two antibodies were used to label for amyloid in the CNS – 10
slides/antibody/per mouse (see Materials and Methods subsection Antibodies). The Aβspecific immunolabeling observed (Figure 5) was comparable to Aβ-specific
immunolabeling noted previously [7].
At 7 days post-infection histologic samples from three mice injected with C.
pneumoniae and one control mouse injected with vehicle only (HBSS) were observed.
Deposits were detected via immunohistochemistry in 3 of 3 infected mice, using the
polyclonal Aβ-specific antibody and detected in 2 of 3 infected mice, using the
monoclonal Aβ6E10 antibody. No deposits were observed in the uninfected mouse with
either antibody, at this time point (Table 3). The average number of deposits for the
infected mice at this time point using the Aβ 1-42 antibody was 4 ± 2.89 and with the
Aβ6E10 antibody the average number of deposits was 5 ± 4.12. Within 0.84 mm of
Bregma (the location of the injection site) in both the rostral and caudal directions, 26 of
27 (96%) total amyloid deposits were detected (Table 5).
The day 14 time point included three mice injected with C. pneumoniae and one
mouse that served as the no-injection control. Deposits were detected via
immunohistochemistry in 2 of 3 infected mice, using the polyclonal Aβ-specific
antibody, and detected in 3 of 3 infected mice, using the monoclonal Aβ6E10 antibody
(Table 3). Two deposits were observed in the uninfected mouse labeled with the Aβ 1-42
antibody. The average number of deposits for the infected mice at this time point using
the Aβ 1-42 antibody was 5 ± 3.69 and with the Aβ6E10 antibody the average total
number of deposits was 6 ± 4.32. Within 0.84 mm of Bregma (the location of the
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injection site) in both the rostral and caudal directions, 13 of 32 (41%) total amyloid
deposits were detected (Table 5).

III.

Identification of Activated Glial Cells in the CNS

Activated glial cells were detected in the CNS of the mice, via
immunohistochemistry, following direct intracranial infection with C. pneumoniae. As
described earlier (see Materials and Methods subsection Mouse Brain), a total of 80
coronal brain sections, 10 per mouse, were immunolabeled with glial fibrillary acidic
protein (GFAP)-specific antibody and analyzed via microscopy. For each mouse, the
slides labeled with GFAP were matched to comparable representative coronal sections
from the Mouse Brain Library (See Materials and Methods subsection Mapping
Immunolabeling on Mouse Coronal Schematics). Activated glial cells were
immunoreactive with GFAP-specific antibody and associated with a nucleus in the CNS
(Figure 6, right column, see arrows). Regions of the brain section that contained a high
density of activated glial cells were circled on the representative coronal sections (see
green circles in Figure 6, left column and Figures 7 and 8, right columns).
At 7 and 14 days post-infection global activation of glia was observed in the CNS
of infected mice. The number of regions with activated glial cells was greater in the
infected mice compared to uninfected controls at both time points (Figure 6). The
hippocampus and dentate gyrus, regions of the brain significant in AD, of infected vs.
uninfected mice were compared. The comparison of tissue from an infected mouse to a
control, or uninfected mouse, at each time point illustrates a substantial difference in total
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number of activated glial cells (Figure 6, center column). Activated glial cells were
observed in regions of interest in AD, such as thalamus, hippocampus and entorhinal
cortex, as well as areas not significantly affected early on in the disease (Figures 7 and 8,
right columns).
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Figure 4. C. pneumoniae-specific labeling in the brains of intracranially infected
mice

These images represent C. pneumoniae labeling, which includes extracellular and
intracellular, observed in the brains of experimental mice at both 7 and 14 days postinfection. A) Representative image of extracellular labeling of C. pneumoniae. B)
Representative image of labeling of C. pneumoniae associated with a blood vessel. C)
Representative image of labeling of intracellular C. pneumoniae. (Size bar = 100 µm)
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Table 3. Total amount of C. pneumoniae-specific labeling

Control
Infected
Infected
Infected

7 Days Post-Infection
27
129
4
70

14 Days Post-Infection
18
111
4
64

The total amount of C. pneumoniae-specific immunoreactive sites observed at
both 7 and 14 days post-infection is displayed above. The mean number of
immunoreactive sites for the infected mice at day 7 was 68 ± 51.06 and the mean number
of immunoreactive sites for the infected mice at day 14 was 60 ± 43.79.
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Figure 5. Amyloid deposits in the brains of intracranially infected mice

These images represent amyloid labeling observed for experimental mice at both
7 and 14 days post-infection. The top corners of each image are inset with a higher
magnification image of amyloid deposits as designated by the low magnification arrow.
A and B) Representative images of amyloid deposits observed using the Aβ 1-42
antibody are presented here. C and D) Representative images of amyloid deposits
observed using the Aβ6E10 antibody are presented. (Size bar = 100 µm)
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Table 4. Total number of amyloid deposits

Control
Infected
Infected
Infected

Total Amount of Aβ
(7 Days Post-Infection)
Aβ 1-42
Aβ6E10
0
0
8
4
1
0
4
10

Total Amount of Aβ
(14 Days Post-Infection)
Aβ 1-42
Aβ6E10
2
0
5
4
9
2
0
12

The total number of amyloid deposits observed at both 7 and 14 days postinfection is presented here. Labeling with two antibodies specific for Aβ 1-42 antigen,
Aβ 1-42 and Aβ6E10 (see Materials and Methods subsection Antibodies), were used to
obtain this data. The mean number of deposits for the infected mice at day 7, using the
polyclonal Aβ-specific antibody, was 4 ± 2.89 and for the infected mice, using the
monoclonal Aβ6E10 antibody, the mean was 5 ± 4.12. At 14 days post-infection the
mean number of deposits for infected mice, using the polyclonal Aβ-specific antibody,
was 5 ± 3.69 and for the infected mice, using the monoclonal Aβ6E10 antibody, the mean
was 6 ± 4.32.
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Table 5. Distribution of C. pneumoniae and amyloid deposits

Rostral
Section
Locations (mm)

Bregma

Caudal

1.98

1.70

1.32

0.74

0.38

0.00

-0.82

-0.94

-1.28

-1.64

-2.12

-2.75

-2.92

-3.80

-4.20

-4.60

-4.92

-

-

-

-

-

-

-

-

27

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

1

16

35

35

24

56

33

-

2

1

-

-

-

-

-

-

-

-

0 (0)

-

-

-

-

0 (0)

0 (0)

0 (-)

-

-

-

-

-

-

-

0 (0)

2 (8)

8 (1)

-

0 (5)

2 (0)

0 (-)

1 (0)

0 (0)

-

-

-

-

-

-

-

1

0

6

-

2

9

-

-

-

-

-

1

11

4

5

2

-

-

-

11

9

-

-

106

30

0

-

-

-

0 (0)

-

0 (0)

0 (0)

0 (0)

-

-

0 (0)

0 (0)

-

-

2 (0)

0 (0)

-

-(1)

0 (1)

1 (-)

0 (1)

5 (-)

3 (1)

-

-

0 (3)

0 (7)

-

-

0 (3)

5 (1)

- (0)

Day 7
Cpn
Antigen
Amyloid
Deposits
Aβ1-42
(Aβ6E10)
Day 14
Cpn
Antigen
Amyloid
Deposits
Aβ1-42
(Aβ6E10)

Control
27
Experimental
203
Control
0 (0)
Experimental
13 (14)
Control
18
Experimental
179
Control
2 (0)
Experimental
14 (18)

-

-

The distribution of C. pneumoniae (Cpn) immunoreactive sites and amyloid deposits in both infected and uninfected, control, mice at 7 and 14 days
post-infection are displayed above. The total number of immunoreactive sites or deposits observed are listed beneath the designated group – control or
experimental. For each time point there are control groups n=1 and the experimental groups n=3. Bregma, -2.12 mm, is the anatomical location of the injection
site for the intracranial injections in the mice. The red text highlights the data selected as being proximal to the injection site (within 0.84mm of Bregma in both
the rostral and caudal directions) and the other numbers in the table are considered as data that is distal to the injection site. The dashes (-) are placed in the table
to indicate sections we did not have to analyze for this project. The data from both amyloid antibodies is expressed in the order: number of labels detected using
Aβ1-42 (number of labels detected using Aβ6E10).
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Figure 6. Distribution of C. pneumoniae-specific immunoreactive sites, amyloid
deposits and activated glial cells at 7 days post-infection

C. pneumoniae immunoreactive sites (red dots), Aβ deposits (blue dots) and
regions of the brain with glial cell labeling (green circles or red arrows) from individual
slides in the day 7 group are presented here in areas of the hippocampus and dentate
gyrus, as well as regions not affected early on in Alzheimer’s disease.

38

Figure 7: Distribution of C. pneumoniae-specific immunoreactive sites, amyloid
deposits and activated glial cells at 14 days post-infection

C. pneumoniae immunoreactive sites (red dots), Aβ deposits (blue dots) and
regions of the brain with glial cell labeling (green circles or red arrows) from individual
slides in the day 14 group are presented here in areas of the frontal cortex, hippocampus
and dentate gyrus, as well as regions not affected early on in Alzheimer’s disease.
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Figure 8. GFAP-specific immunoreactivity in brain tissue of infected and control
mice
Regions of the brain – hippocampus and dentate gyrus, which are relevant structures in the AD
brain – were selected to illustrate the difference in amount of glial cell labeling observed between a control
and an experimental mouse at each time point. Substantial glial cell labeling was observed in the infected
mice and comparable sections in controls were selected for comparison. The red boxes in the left column
of images represent the region of the section observed at higher power, which are those located in the
center column. The red boxes in the center column of images represent the region of the section observed
at an additionally increased power, which are those located in the right column. A) This row represents day
7 data from an uninfected, vehicle injected control, mouse. B) This row represents day 7 data from an
infected mouse. C) This row represents day 14 data from an uninfected, no-injection control, mouse. D)
This row represents day 14 data from an infected mouse. (Size bar = 100 µm)
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Discussion

I.

Summary of Results

The brains of 8 BALB/c mice, 3 infected and 1 control for each of the two time
points, days 7 and 14, were analyzed for this project (Table 1). The mice were infected,
via direct intracranial injection, with a respiratory isolate (AR-39) of Chlamydia
pneumoniae. The control mice that were analyzed were either injected with vehicle only
(HBSS), day 7 group, or not injected, day 14 group. Brain tissue sections from all mice
were immunolabeled and analyzed for the presence of C. pneumoniae antigen, amyloid
plaques and activated markers in glial cells.
At 7 days post-infection the average C. pneumoniae antigen burden for the 3
infected mice was 68 ± 51.06. For the 3 infected mice 82% (166 of 203) of the total
immunoreactive sites were identified within 0.84 mm of Bregma, the location of the
injection site (Figure 3 and Table 5). For the vehicle only control mouse, 100% (27 of
27) of the C. pneumoniae-specific immunoreactive sites were located in this region. At
day 14 post-infection, the average C. pneumoniae antigen burden for the 3 infected mice
was 60 ± 43.79. For these mice 70% (126 of 179) of the total C. pneumoniae-specific
immunoreactive sites were detected within 0.84 mm of Bregma (Table 5). The control
mouse at this time point had 94% (17 of 18) of the C. pneumoniae-specific
immunoreactive sites in this region.
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Amyloid deposits were detected in 3 of 3 infected mice, using polyclonal Aβspecific antibodies and detected in 2 of 3 infected mice, using the monoclonal Aβ6E10
antibody, at 7 days post-infection (Table 4). No deposits were observed in the uninfected
mouse with either antibody. The average number of deposits for the infected mice at 7
days post-infection, using the Aβ 1-42 antibody, was 4 ± 2.89 and with the Aβ6E10
antibody the average number of deposits was 5 ± 4.12. For all amyloid specific
immunoreactivity, 26 of 27 (96%) total amyloid deposits were detected within 0.84 mm
of Bregma in the infected mice (Table 5). At 14 days post-infection, amyloid deposits
were detected via immunohistochemistry in 2 of 3 infected mice, using the polyclonal
Aβ-specific antibodies, and detected in 3 of 3 infected mice, using the monoclonal
Aβ6E10 antibody (Table 4). Two deposits were observed in the uninfected mouse
labeled with the Aβ 1-42 antibody. At 14 days post-infection, the average number of
deposits for the infected mice at this time point, using the Aβ 1-42 antibody, was 5 ± 3.69
and with the Aβ6E10 antibody the average total number of deposits was 6 ± 4.32. For all
amyloid specific immunoreactivity, 13 of 32 (41%) total amyloid deposits were detected
within 0.84 mm of Bregma in the infected mice and 2 of 2 deposits were detected in this
region in the control mouse (Table 5).
Global activation of glia was observed in the CNS of infected mice at both 7 and
14 days post-infection. The number of regions with activated glial cells was greater in
the infected mice compared to uninfected controls at both time points (Figure 6). The
hippocampus and dentate gyrus of an infected mouse was compared to that of a control
mouse. At each time point a substantial difference in the total number of activated glial
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cells was noted between the infected and uninfected mice in these regions with infected
mice clearly having a greater number of activated glia (Figure 6).

II.

Relationship between C. pneumoniae, Inflammation and Amyloid

Although the role of infection in AD is still debated, the concept of an infection
playing a role in the neuroinflammatory cascade has gained increased recognition [5, 40].
Many of the laboratories that study infection and AD focus specifically on the role of
infection with C. pneumoniae in the initiation and progression of late-onset Alzheimer’s
disease. The initial study in 1998 by Balin and co-workers compared human non-AD
control brain tissue to AD brain tissue post-mortem [26]. In this study using RT-PCR
specific for C. pneumoniae, they detected C. pneumoniae in 17 of 19 AD brains, while
only 1 of 19 control brains had detectable levels of C. pneumoniae. In addition, C.
pneumoniae was found in areas of typical AD neuropathology and the organism was
confirmed in perivascular macrophages, pericytes and microglia. In 2000, two additional
laboratories published their findings on the presence of C. pneumoniae in AD brain tissue
[41, 42]. Mahony and co-workers found that 18 of 21 AD brains were positive for C.
pneumoniae. Ossewaarde and co-workers found that 92% of the AD brains they analyzed
were positive for C. pneumoniae [41, 42].
Recent studies in this laboratory [7] support previous research that indicates that
C. pneumoniae is capable of entering the CNS following intranasal inoculation. Once C.
pneumoniae has entered the CNS C. pneumoniae stimulates the deposition of amyloid
[7].

43

To expand our understanding of the role of infection and inflammation in amyloid
deposition in AD, we compared our data with data obtained from previous work in this
laboratory [7]. Following intranasal inoculation with C. pneumoniae, the C. pneumoniae
burden peaks at 1 month post-infection and a subsequent peak in amyloid burden occurs
at 2 months post-infection. The C. pneumoniae burden decreased at 2, 3 and 4 months
post-infection and the number of amyloid deposits decreased after 2 months and at the 3
and 4 month time points. This suggests that C. pneumoniae infection induces an
inflammatory response and an up-regulation of Aβ production and subsequent deposition.
Once the C. pneumoniae antigen or the infection burden decreases, the activated glia
appear to reverse the process of amyloid deposition and the number of deposits decreases.
In this project at days 7 and 14 following direct intracranial injection with C.
pneumoniae, substantial C. pneumoniae antigen was detected, a glial cell response was
identified, and amyloid beta deposition was initiated in the infected mice. The greatest C.
pneumoniae antigen burden was localized to regions near the injection site at day 7, but at
day 14 C. pneumoniae was identified in more distal regions of the CNS (Table 5). At
both days 7 and 14, C. pneumoniae was detected in both hemispheres. These data
suggest that C. pneumoniae infection spreads from the site of injection and disseminates
to more distant regions of the CNS. Following the intranasal inoculations, the C.
pneumoniae antigen appears to be detected in the olfactory bulbs and frontal cortical
regions at early time points and spreads from these areas, which are proximal to the site
of inoculation, and then to other regions of the CNS more distant to the initial site of
infection. Based on the route of inoculation the majority of antigen is proximal to the site
of injection, and at later time points, it spreads from this location (unpublished
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observations). The results obtained in this project confirm that an inflammatory response
is induced in the CNS following direct intracranial infection with the organism and that
infection within the CNS with the organism induces amyloid deposition.
Global glial cell activation was observed in the CNS of infected mice following
direct intracranial infection. Glial cell activation was observed in regions where no C.
pneumoniae antigen was detected. This may be in response to soluble C. pneumoniae
antigen or possibly soluble Aβ antigen. Another group found that increased Aβ activates
microglia and astrocytes and promotes the release of inflammatory mediators and
amyloid deposition [9]. Previous research supports the role of soluble Aβ promoting
glial cell activation and unpublished observations in this laboratory indicate that
following infection with C. pneumoniae, high antigen burden precedes high Aβ deposits;
following reduction and clearance of C. pneumoniae antigen, the number of Aβ deposits
decreases. This suggests that in this experimental system, C. pneumoniae infection is the
primary factor that induces and promotes amyloid deposition [7]. Glial cell activation
appears to contribute to limiting C. pneumoniae replication and ultimately to resolving
the infection in the CNS [35].
Previous findings in this laboratory indicate that C. pneumoniae antigen peaks 28
days post-intracranial infection and then decreases at subsequent time points
(unpublished observations). At 56 days post-infection, amyloid deposition peaks and
then drops at subsequent time points (days 84 and 106 days post infection), but no
analysis of glial cell activation was performed in the previous studies. Others who have
studied the relationship between C. pneumoniae, Aβ and glia have found that this
organism enhances microglial activation [38]. Glia have been shown to be
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chemotactically attracted to Aβ [43]. Previous research illustrates that Aβ is
constitutively produced by normal neuronal cells and microglia and astrocytes appear to
be involved with normal clearance [44]. C. pneumoniae infection serves as a stimulus for
inflammation, and glial cell activation plays a role in amyloid deposit (plaque)
biogenesis.
Both C. pneumoniae antigen and glial cell activation contribute to amyloid
deposition in BALB/c mice infected via direct intracranial injection. At day 7, amyloid
deposits were localized to regions near the injection site, but at day 14, the deposits were
located in regions more distal to the injection site (Table 5). This parallels our
observations for C. pneumoniae antigen at 7 and 14 days post-infection. Although
amyloid deposits were identified in the infected mice, the total number was not as
substantial as that found in previous studies at the time of peak deposition. At day 7 and
14 we observed approximately 4 total amyloid deposits per mouse, whereas in preceding
studies (unpublished observations), the total number of deposits at the time of peak
deposition (56 days post-infection) was approximately 36 per mouse. The amount of
deposits we observed in this study (approximately 4 per mouse) was comparable to the
day 84 time point from the previous study (approximately 6 per mouse). Although few
amyloid deposits were detected, we observed global glial cell activation, likely a result of
a high burden of soluble amyloid. A high burden of organism at 28 and 56 days results in
accumulation of amyloid deposits [7]. Once C. pneumoniae antigen began to decrease,
the number of amyloid deposits decreased substantially.
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Initial Stimulus (i.e.Chlamydia pneumoniae infection)

Aβ deposition

Glia activation

IL-1-β, IL-6, other proinflammatory mediators

Neuronal damage
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Disease Promotion

Short Term

Disease Prevention

Figure 9. Contributing factors in late-onset Alzheimer’s disease.

Chronic inflammation and amyloid deposition are two hallmarks of Alzheimer’s
disease. We hypothesized that we would observe C. pneumoniae antigen and glial cell
activation in the CNS following direct intracranial infection with C. pneumoniae. We did
obtain these results, but we found that C. pneumoniae antigen is not always present in the
same regions in which we observe glial cell activation (Figure 9). Furthermore, we found
substantial amounts of activated glial cells in infected mice compared to uninfected mice
(Figure 6). These data suggests that the presence of C. pneumoniae antigen may not be
the only trigger for glial cell activation in this system and that glia may be responding to
the presence of soluble amyloid as well as soluble C. pneumoniae antigen such as
lipopolysaccharide (LPS). Given that amyloid deposition was observed, we assume that
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the total amyloid burden, soluble plus deposited amyloid, is high since this is consistent
with previous findings. We hypothesized that amyloid deposits would be observed in
regions where inflammation occurs; however, glial cell activation was not co-localized
with or concentrated solely around Aβ deposits solely. This attraction was more of a
global phenomenon suggesting some soluble stimulus such as C. pneumoniae antigen or
Aβ were possible triggers for glial cell activation and inflammation, which would
contribute to the formation and deposition of β amyloid.

III.

Application of AD Mouse Model to AD in the Human Brain

This project supports the role of C. pneumoniae infection as one of the possible
factors contributing to neuropathology in late-onset Alzheimer’s disease. The prevalence
of infection with C. pneumoniae in the population is about 40% and this organism can
infect the same host multiple times throughout their lifetime [32, 33]. These data
obtained in this study confirm those of previous studies that have shown that C.
pneumoniae is capable of establishing an infection and producing AD-like pathology in
BALB/c mice [7]. This laboratory has also studied the effects of exposing mice to C.
pneumoniae at multiple times (unpublished observations). These data suggest that ADlike pathology increased in a step-wise fashion following multiple exposures. Thus, reexposure may have an additive or progressive effect.
This project also confirms the ability of this organism to induce an inflammatory
response in the CNS that appears to contribute to the deposition of amyloid in the brain.
In addition to the presence of AD-like pathology, several inflammatory mediators have
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been observed around amyloid deposits. This suggests that the inflammatory response
may be contributing to the presence and onset of pathology (unpublished observations).
As all individuals age, it is important to recognize that their immune systems
change and they are not as capable of fighting and clearing infections and amyloid
deposits as would be younger individuals. Many studies have suggested that as we age,
we are more susceptible to infections and re-exposure to an organism such as C.
pneumoniae is a likely probability in our aging populations [45]. Individuals who are
exposed to this organism may become infected, and once infected they may develop
chronic inflammation in the CNS. Infection and chronic inflammation together could
contribute to cumulative amounts of amyloid deposits that, over time, cannot be cleared
from the CNS thus contributing to AD pathology and eventual symptomatology.
Therefore, infection with an organism such as C. pneumoniae may be one factor that
initiates an inflammatory response that could result in the neuropathology consistent with
late-onset Alzheimer’s disease.

IV.

Future Directions

This study confirms results obtained from preceding studies in this laboratory and
expands our understanding of the ability of C. pneumoniae to establish an infection in the
CNS. Further, this infection appears to elicit an inflammatory response and contribute to
the production of amyloid deposits. However, further research is necessary to determine
the length of time needed, following infection with C. pneumoniae, to induce the
processes involved in the production of AD-like pathology that may ultimately contribute
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to AD symptomatology. This project illustrates the ability of C. pneumoniae to establish
a CNS infection as early as 7 and 14 days following direct intracranial infection with the
organism in the brain of a BALB/c mouse. In addition, we observed an inflammatory
response as depicted by the presence of activated glial cells as well as the deposition of
Aβ at both time points in the CNS of a BALB/c mouse.
Previous studies in this laboratory have found that following intranasal
inoculation with C. pneumoniae, the highest burden of C. pneumoniae antigen was
observed 1 month after infection and then the burden decreases at 2, 3 and 4 months postinfection [7]. In the same experiment they found that amyloid deposition was low at 1
month post-infection, but increases and peaks at 2 months post-infection, subsequently
decreasing at 3 and 4 months. It seems that the greatest amount of amyloid deposition
occurs after the greatest burden of C. pneumoniae in the CNS, which is supported by the
observations in this project that found that 14 days post-infection may be too early to
detect a substantial number of amyloid deposits.
In this project we saw limited deposits in the brains of BALB/c mice; however we
did see an inflammatory response in the infected mice even with this minimal deposition,
which indicates that other triggers for inflammation may be present in this system for
studying late-onset Alzheimer’s disease. Future considerations for this project should
include performing an ELISA to detect the amount of soluble amyloid at each of the
specified time points. Detecting the total amyloid burden, soluble plus insoluble
amyloid, may contribute to our understanding of the role of soluble amyloid in glial
activation and eventual deposition. Previous data indicates that in order for amyloid to
deposit there must be a high total burden of amyloid. Since we saw deposits in the mice
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analyzed for this project, we have hypothesized that there is a high burden of total
amyloid in the CNS of the mice contributing to amyloid deposition.
One of the major limitations of this project was that there were a small number of
mice analyzed for data collection. It is necessary to increase the number of mice
analyzed for each time point so that statistical significance with greater power can be
obtained. Also, it would be ideal to have the same number of control and experimental
mice analyzed for each of the time points. For example, in this project only one control
was analyzed at each time point and of those two controls one was a no injection control
and the other was a vehicle only control. Analyzing more coronal sections that represent
the area of the brain of interest would also be beneficial to obtain a better statistical
sampling (Table 5).
As further work is completed for this project, another consideration should
include increasing the number of mice analyzed at later time points following direct
intracranial infection with C. pneumoniae. Days 28, 42 and 56 post-infection should be
evaluated to determine if more amyloid deposits would be detected at greater lengths of
time after infection. These time points are significant because we have collected data in
previous studies at these times following intranasal inoculation [7]. In these previous
projects, the analysis showed that amyloid deposition peaked following a peak in C.
pneumoniae burden. Therefore, we may only have seen limited amyloid deposition
because a limited number of sections were analyzed for these time points following
infection that would determine substantial deposition.
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Figure 10. Relationship between C. pneumoniae-specific immunoreactive sites,
amyloid deposits and activated glial cells

The red dots represent C. pneumoniae antigen, the blue dots represent amyloid
beta deposition (labeled with either Aβ 1-42 or Aβ6E10 antibody – Materials and
Methods subsection Antibodies) and the green circles and red arrows represent glia
labeling.
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